Related Experiment Video
Updated: May 22, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
New directions for biologic targets in urothelial carcinoma
Suzanne Richter1, Srikala S Sridhar
1Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Abstract:
Urothelial carcinoma remains an important oncologic problem with significant morbidity and mortality. This article provides an overview of the current status of treatment of urothelial carcinoma, with an update on current trials and recent American Society of Clinical Oncology abstracts. As an alternative to focusing on the metastatic setting, we take a broad look at drug development to date, as it spans from early disease to advanced disease in the context of emerging molecular data. This approach allows us to show that each stage involves key considerations based on emerging evidence regarding molecular biology, stage-specific novel endpoints, and rational patient selection that may help further trial designs in the future. Key issues, such as neoadjuvant versus adjuvant perioperative chemotherapy, approaches to salvage second-line therapy in the metastatic setting, and treatment of elderly and cisplatin-ineligible patients, are discussed. New paradigms in clinical research, including novel endpoints, upfront rational patient selection, biomarkers, and trial design, are also addressed.
Insights
Urothelial carcinoma treatment is evolving, integrating molecular data across all disease stages. Future trials will focus on novel endpoints and patient selection for improved outcomes in bladder cancer.
Area of Science:
- Oncology
- Urothelial Carcinoma Research
- Drug Development
Background:
- Urothelial carcinoma presents significant morbidity and mortality.
- Current treatment strategies require updates based on emerging data.
- A comprehensive overview of drug development is needed.
Purpose of the Study:
- To provide an overview of urothelial carcinoma treatment.
- To update on current trials and recent clinical oncology abstracts.
- To examine drug development from early to advanced disease stages.
Main Methods:
- Reviewing current treatment status and drug development.
- Analyzing emerging molecular data in urothelial carcinoma.
- Discussing neoadjuvant vs. adjuvant chemotherapy and salvage therapies.
Main Results:
- Treatment considerations vary by disease stage, informed by molecular biology.
- Novel endpoints and rational patient selection are crucial for future trial designs.
- Key issues include perioperative chemotherapy, second-line therapy, and special patient populations.
Conclusions:
- Integrating molecular insights into urothelial carcinoma treatment is essential.
- Future clinical research should emphasize novel endpoints, biomarkers, and rational patient selection.
- Optimized trial designs can improve outcomes for patients with urothelial carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:56Treatment Resistant Cancers